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The HIV-1 exterior envelope glycoprotein gp120 binds receptor (CD4) and co-receptors (CCR5/CXCR4) and is a major target for
neutralizing antibodies. The two functionally conserved regions of gp120 involved in receptor binding are conformational in nature. It is
likely that the elicitation of neutralizing antibodies to these targets will benefit by presentation of these sites to the humoral immune system
under physiologic conditions. Initially, we investigated the ability of the molecular adjuvant C3d to enhance antibody responses to variant
gp120 glycoproteins in phosphate-buffered saline (PBS). We utilized a gp120 variant glycoprotein deleted of N- and C-terminal sequences
(gp120DC1/C5) originally designed to eliminate immunodominant, non-neutralizing epitopes and characterized this protein when fused to
two C3d elements (gp120DC1/C5(C3d)2). In PBS, the gp120DC1/C5(C3d)2 proteins are able to elicit gp120 binding antibodies more
efficiently than gp120 lacking C3d moieties. We then asked if we could observe C3d-enhanced immunogenicity of gp120 in the presence of
the classical oil-in-water adjuvant, Ribi. In the presence of the Ribi, which contains the TLR-4 agonist monophospholipid A (MPL),
antibodies elicited by the gp120DC1/C5(C3d)2 were of higher titer than those elicited by the identical protein in PBS. To determine if the
elicited secondary response was due to a synergy between the C3d repeats and the Ribi, we then inoculated gp120DC1/C5 protein in Ribi and
observed that similar titers of anti-gp120 antibodies were elicited in comparison to the gp120DC1/C5(C3d)2 protein also inoculated in Ribi
adjuvant. In Ribi, there was a small but consistent increase in gp120-specific antibody titer of a gp120DC1/C5(C3d)2 prime followed by two
gp120DC1/C5 boosts compared to three inoculations of either the gp120DC1/C5 proteins or the gp120DC1/C5(C3d)2 proteins alone. We
conclude that the molecular adjuvant C3d demonstrates utility in conditions where physiologic presentation of native protein structures is
desired, but may have less benefit in the context of a relatively potent protein adjuvant such as Ribi.
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E-mail address: richardwyatt@nih.gov (R. Wyatt).then, following conformational changes, binding to the
chemokine receptor co-receptors, either CCR5 or CXCR4
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996).
Due to its necessary location on the surface of the virus to
engage receptor, gp120 is also a major target for neutralizing
antibodies (Wyatt and Sodroski, 1998; Wyatt et al., 1998).
Since most effective anti-viral vaccines that protect against
viral challenge do so in part, or wholly, by neutralizing
antibody responses (Pantaleo and Koup, 2004), the elic-05) 277 – 284
Fig. 1. Schematic depiction of a gp120DC1/C5(C3d)2 fusion protein
interacting with two CD21 molecules (CR2) on the surface of a gp120-
specific B cell. The molecule CD19 is associated with CD21 as part of a
signaling complex. Co-ligation of CD21 and surface IgM (sIgM) lowers the
apparent amount of antigen required for B-cell activation, although other
CD21-independent pathways may exist.
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for vaccine development. Means to enhance (‘‘adjuvanate’’)
antibody responses to gp120 are therefore of great interest.
The use of adjuvant to better elicit antibody responses to
soluble proteins is a proven methodology; however, only
one adjuvant (alum) is currently approved for human use.
Interest in using the so-called molecular adjuvants, with
more specific and molecularly defined modes of action,
has grown over recent years. One relatively well-studied
molecular adjuvant is a component of the complement
pathway known as C3d, which, as a fusion protein, has
been shown to possess adjuvant properties (Dempsey et
al., 1996). In a series of papers, Ross and colleagues have
shown that proteins, including the HIV-1 envelope
glycoproteins, fused with C3d repeats and expressed in
vivo from plasmid DNA demonstrate enhanced immuno-
genicity and, in one case, improved neutralizing antibody
responses (Bower et al., 2004a, 2004b; Green et al., 2003;
Liu et al., 2004; Ross et al., 2001). Raising anti-Env
antibody responses under physiologic, non-denaturing
conditions might increase the likelihood of eliciting
responses to the conserved, conformation-dependent neu-
tralization epitopes present on the HIV-1 envelope glyco-
proteins. In addition, it is possible that C3d repeats will
synergize with classical oil-in-water adjuvants such as
Ribi. Besides properties of protein deposition, the Ribi
formulation used in mice activates the immune system by
direct interaction of its monophospholipid A (MPL)
component with toll-like receptor 4 (TLR-4) found on
antigen-presenting cells such as dendritic cells (Baldridge
et al., 2004; Miller et al., 2005).
The complement protein, C3d, plays a key role in linking
the innate immune system to antigen-specific antibody
formation. In the absence of antibody, foreign proteins or
microorganisms can activate the complement system though
the alternative pathway by proteolysis of the complement
protein, C3, to generate C3b. Activated C3b contains a highly
reactive internal thiol ester, which can covalently attach to
available protein amine groups or to hydroxyl groups present
on carbohydrate-containing glycoproteins of the invading
microorganism. Once covalently linked to the foreign
protein, C3b undergoes a further proteolytic modification to
generate C3d, which results in a C3d-tagged protein. The
C3d-tagged proteins have the capacity to bind complement
receptors (CD21, previously designated CR2) expressed on
the surface of B cells (Molina et al., 1992). In this model, B-
cell clones possessing surface IgM (sIgM) that recognize an
epitope on the C3d-tagged protein become preferentially
activated by the cross-linkage created by the C3d-tagged
protein being bound simultaneously to CD21 (via the C3d
moiety) and to sIgM (via epitopes on the foreign protein; for
example, gp120-C3d; see Fig. 1). Signaling to downstream
intracellular pathways is mediated by the CD21-associated
molecule, CD19.
The initial observations of Dempsey et al. exploited the
ability of C3d to target a model protein (hen egg whitelysozyme; HEL) to complement receptors on B cells (and
perhaps other immune cell types) to enhance the immunoge-
nicity of HEL-C3d fusion proteins possessing one, two or
three repeats of the C3d moiety. Mice immunized with HEL-
C3d fusion proteins in phosphate-buffered saline as a primary
inoculation, followed by a HEL protein boost in adjuvant,
elicited IgG antibodies at a level comparable to that achieved
with HEL as a prime in complete Freund’s adjuvant (CFA)
(Dempsey et al., 1996). Experimentally, the apparent co-
ligation of CD21/19 and sIgM lowers occupancy of the
number of antigen receptors required for B-cell activation by
two orders of magnitude andmay be the mechanism bywhich
sIgM-CD21 cross-linking increases B-cell activation. Since
the follicular dendritic cells (FDCs) also express CD21
molecules, they too may be activation targets of the C3d-
tagged immunogens. However, a more recent study observed
enhancement of IgG secondary antibody responses to C3d-
ligated proteins in CD21/35-deficient mice and suggested
that C3d may also act via an as-yet-to-be-identified CD21-
independent pathway (Haas et al., 2004). Therefore, it is
possible that CD21-negative cells may also participate in the
immune-enhancing effects of C3d during natural infection or
following immunization.
In any case, the use of C3d as a ‘‘molecular adjuvant’’ thus
provides an attractive means of eliciting a high-titer antibody
response under conditions in which it may be desirable to
avoid the use of (potentially) denaturing adjuvants, such as
preservation of the quaternary structure of a complex protein
immunogen. A recent study has suggested that three repeats
of C3d appended to trimeric HIV-1 envelope glycoproteins
expressed by injection of plasmid DNA more effectively
elicited neutralizing antibodies to primary isolates than
vectors encoding for only the envelope glycoproteins (Bower
et al., 2004b).
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responses to gp120 proteins fused to three repeats of C3d and
inoculated two times into wild-type C57Bl/6 mice (Haas et
al., 2004). In contrast, if the gp120-C3d3 was expressed from
DNA, or was inoculated into CD21-deficient ‘‘knockout’’
mice as protein, increased antibody responses were better
elicited by the gp120-C3d3 fusion as compared to wild-type
gp120. In our current study, we sought to determine if
enhanced immunogenicity to gp120 could be observed with
two fused repeats of C3d inoculated at a lower dose into wild-
type Balb/c mice, and if enhancement would persist over
repeated inoculations. According to the model proposed by
Dempsey et al., such gp120-C3d fusion proteins would be
capable of binding to CD21 on the surface of B cells and
FDCs (Fig. 1). We then asked if there were a difference in
outcome if we primed with the gp120 fused to C3d and then
boosted with proteins either containing or lacking C3d.
Finally, we determined if we could still detect enhanced IgG
antibody responses to gp120-C3d fusion proteins in the
presence of classical adjuvant.
We initially examined the effects of fusing two repeats of
C3d to a gp120 variant glycoprotein harboring deletions at
the N- and C-termini (gp120DC1/C5(C3d)2) on protein
expression, folding and immunogenicity. The gp120DC1/
C5 construct was originally designed to eliminate immuno-
dominant, non-neutralizing determinants present on gp120
(Grundner et al., 2004) and was used as a control protein in
the current study. Immunogenicity experiments with the two
proteins in PBS demonstrated that, indeed, the two C3d
repeats fused to gp120 glycoproteins significantly enhanced
the elicitation of secondary IgG antibodies to gp120. We
then examined the immunogenicity of gp120DC1/C5(C3d)2
proteins in the classical oil-in-water adjuvant, Ribi. Ribi
adjuvant contains the TLR-4 agonist MPL as a major
immune-activating component and we sought to determine
if there is a detectable additive or synergistic effect in
eliciting anti-gp120 IgG secondary responses between the
two types of adjuvants targeting distinct innate immune
pathways. We report that, as opposed to a clear enhanced
effect of the fused C3d repeats on gp120 immunogenicity in
PBS, in the classical oil-in-water adjuvant Ribi, there was
less observable benefit of fused C3d repeats on the
elicitation of gp120-directed IgG antibodies. In Ribi
adjuvant, when the gp120DC1/C5(C3d)2 proteins were used
as a prime, followed by two gp120DC1/C5 boosts, there
was a slight but consistent increase in elicited anti-gp120
titers as determined by anti-gp120 IgG ELISA.Fig. 2. Analysis of the gp120DC1/C5 and gp120DC1/C5(C3d)2 glyco-
proteins expressed from Drosophila S2 cells. Panel A, a Coomassie blue-
stained SDS gel of recombinant proteins purified by F105 affinity
chromatography; panel B, immunoprecipitations with the designated
monoclonal/CD4 and polyclonal antibodies; panel C, iodinated
gp120DC1/C5 and gp120DC1C5(C3d)2 binding to CD21
+ Raji B cells
followed by immunoprecipitation and autoradiography.Results
Protein characterization and conformational analysis of
gp120 and C3d2 moieties
The purified gp120DC1/C5(C3d)2 fusion proteins were
analyzed to verify that native conformation wasmaintained inboth the gp120 and C3d portions of the molecule by
immunoprecipitations. The gp120DC1/C5 protein was ana-
lyzed in parallel as either a positive or negative control. Both
the gp120DC1/C5 protein and the gp120DC1/C5(C3d)2
fusion proteins were recognized by each of the conforma-
tional antibodies F105 and 17b, indicating that the gp120
domains were in a native conformation following purification
(Fig. 2B). CD4 recognition was assessed indirectly by
induction of 17b binding. AIDS patient sera were used in
antibody excess to determine the total amount of gp120 that
could be efficiently immunoprecipitated in the assay.
Besides noting the increased apparent molecular weight
of the (C3d)2 fusion proteins in SDS gels (Fig. 2A), we
performed two assays to determine both that the C3d
elements were present in the fusion protein and that the C3d
moieties were functional in terms of their ability to bind to
CD21. To simply detect the presence of the C3d moieties,
the fusion proteins were specifically immunoprecipitated by
both anti-mouse-C3 and anti-human-C3d polyclonal anti-
sera (Fig. 2B). To confirm that C3d could recognize CD21
in the context of the fusion protein, a binding assay was
performed with Raji B cells, which express human CD21 on
their cell-surface. Previously, these cells had been shown to
bind fusion proteins containing murine C3d identical to the
Fig. 4. Half-maximal binding to gp120 of IgG from pooled sera of mice
inoculated with gp120DC1/C5(C3d)2 in PBS compared to inoculation in
Ribi adjuvant. Error bars indicate range of values obtained for duplicate
samples.
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In this assay, the 125I-labeled gp120DC1/C5 did not bind to
the Raji cells at a detectable level, whereas the 125I
gp120DC1/C5(C3d)2 glycoprotein efficiently bound to the
CD21+ cells (Fig. 2C), demonstrating that the fusion protein
was targeted to these cells by properly folded C3d moieties.
Taken together, these data strongly suggest that each
element of the gp120DC1/C5(C3d)2 fusion protein is folded
in a functional, native conformation.
Analysis of sera from mice inoculated with gp120
possessing or lacking C3d
To determine the effects of C3d in a physiologic buffer
and in the absence of a classical adjuvant, we analyzed the
levels of anti-gp120 IgG antibodies elicited by the purified
gp120 glycoproteins, either lacking or possessing the two
C3d repeats, following a second, third and fourth inocu-
lation in PBS. Sera derived after each inoculation of the
gp120DC1/C5(C3d)2–PBS proteins exhibited higher titers
of anti-gp120 antibodies when compared to sera elicited byFig. 3. ELISA analysis of pooled sera from mice inoculated with
gp120DC1C5 in PBS as compared to mice inoculated with gp120DC1/
C5(C3d)2 in PBS after 2, 3 and 4 inoculations. Test bleeds were obtained
7–10 days following each inoculation. Error bars indicate range of values
obtained for duplicate samples.the gp120DC1/C5 proteins lacking the C3d repeats, as
determined by IgG ELISA (Fig. 3).
We then sought to determine if the gp120DC1/C5(C3d)2
proteins were more immunogenic in adjuvant such as the
commercially available, MPL-containing adjuvant Ribi.
Since MPL is a TLR-4 agonist, we reasoned that enhanced
immunogenicity might be observed if both CD21 and TLR-
4 pathways were targeted by the gp120DC1/C5(C3d)2
proteins. As seen in Fig. 4, the gp120DC1/C5(C3d)2 in
Ribi did elicit higher-titer anti-gp120 IgG antibodies
compared to animals inoculated with the identical protein
at the identical dose and route, but administered in PBS.
Shown are the half-maximal binding values determined by
ELISA. After 4 inoculations, the half-maximal titer of the
gp120DC1/C5(C3d)2 in PBS did approach the levels of anti-
gp120 IgG antibodies elicited by 3 inoculations of the
proteins in Ribi adjuvant (Fig. 4). Four inoculations of the
proteins in Ribi did not further boost the anti-gp120 IgG
titers (not shown).
These data did not clearly define if there was an additive
affect between the C3d fusion protein and the Ribi, or if the
Ribi components themselves were the major factor con-
tributing to the enhanced elicitation of antibodies by the
gp120DC1/C5(C3d)2 proteins. We then inoculated 3 groups
of mice with selected proteins, all emulsified in Ribi
adjuvant. Group A mice were inoculated three times with
gp120DC1/C5 lacking the C3d repeats, group B mice
received one priming dose of gp120DC1/C5(C3d)2 and
then two boosts of gp120DC1/C5 protein and group C were
inoculated with three equivalent doses of gp120DC1/
C5(C3d)2 glycoproteins. Following the third inoculation,
the sera were analyzed by ELISA and, as seen in Fig. 5, all
three groups displayed a similar pattern of increasing levels
of anti-gp120 IgG antibodies following each inoculation.
However, the mice primed with the gp120DC1/C5(C3d)2
glycoproteins and boosted with the gp120DC1/C5 proteins
(group B) had roughly a 2- to 3-fold higher titer of gp120-
binding IgG antibodies at half-maximal binding compared
to the gp120DC1/C5 priming and boosting (group A). In
this assay, a slightly greater maximal absorbance at the
Fig. 5. ELISA analysis of pooled sera from mice inoculated with one prime
and two boosts of recombinant proteins. Bleeds 1, 2 and 3 were obtained
7–10 days after each inoculation. Group A, gp120DC1C5 prime and boost;
group B, gp120DC1/C5(C3d)2 prime and gp120DC1/C5 boosts; group C,
gp120DC1/C5(C3d)2 prime and boosts. Error bars indicate range of values
obtained for duplicate samples.
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for group B compared to group A after either two or three
inoculations. We also observed that in this experiment, near
maximal IgG titers were elicited by a single protein prime
followed by one protein boost in the Ribi adjuvant (Fig. 5).Discussion
As more complex and hopefully improved HIV-1 Env-
based vaccine candidates are developed, it is important to
define the optimal means to elicit antibodies against theseEnv mimetics. Since most forms of unmodified, monomeric
gp120 have been disappointing in terms of eliciting broadly
neutralizing antibodies in animals and particularly human
clinical trials (Flynn et al., 2005), many investigators have
sought to develop modified immunogens that may better
mimic the conserved regions present on the native viral
spike and thereby better elicit broadly reactive neutralizing
antibodies. Many investigators, including ourselves, are
developing second generation trimeric immunogenic plat-
forms which appear to be the most promising candidates to
more efficiently present conserved epitopes to the host
immune system (Binley et al., 2000; Gao et al., 2005;
Sanders et al., 2002; Srivastava et al., 2003a, 2003b; Yang et
al., 2000a, 2000b, 2001, 2002). In this study we have used a
candidate ‘‘first generation’’ modified monomeric gp120
Env glycoprotein to study the effects on the elicitation of
gp120-directed binding antibodies of two types of adju-
vants: the so-called molecular adjuvant C3d and a more
classical oil-in-water adjuvant, Ribi. The original rationale
for the gp120 modifications was to remove immunodomi-
nant non-neutralizing epitopes on the C- and N-terminus of
gp120. We have previously determined these regions are not
exposed on the trimeric spike (Pancera and Wyatt, 2005;
Wyatt et al., 1997) and we sought to determine if these
modifications would better elicit antibodies directed against
less immunogenic neutralizing determinants still available
on the modified monomer and present on the functional Env
spike (Grundner et al., 2004; Wyatt et al., 1997). In
preliminary data this candidate immunogen did elicit
detectable neutralization of the homologous, lab-adapted
strain HXBc2 and another relatively easy to neutralize
strain, MN, but not the primary isolate 89.6 as determined
by a pseudotype viral entry/neutralization assay. Due to the
limits of sera, confirmatory assays could not be performed
within the scope of this study.
In this report, and as anticipated from most earlier
studies, we have clearly shown that the C3d fusion moieties
enhance IgG secondary antibody responses to gp120
proteins in physiologic saline. It is important to establish
that C3d can enhance gp120 immunogenicity in physiologic
buffer, as this was not observed with gp120-C3d3 proteins in
the context of wild-type C57/Bl6 mice (Haas et al., 2004).
However, since these investigators could observe a benefit
when the same construct was expressed in C57/Bl6 mice
from DNA, it suggested that perhaps, at a lower dose, such a
benefit might be more apparent. In part, this was why we
performed our studies at a lower dose than the previous
study, an aspect that may deserve further investigation.
We also report that in the presence of the classical
adjuvant Ribi, which is designed to both enhance antigen
deposition and activate immune danger signals through
TLR-4, there was less benefit of the fused C3d repeats on
gp120 immunogenicity. The reduced benefit of C3d in Ribi
adjuvant may be due to the activation of CD21-independent
pathways also targeted by C3d (Haas et al., 2004) that are
already maximally activated in the presence of Ribi. We
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gp120 or gp140 immunogens does have benefit in the
presence of physiologic buffers such as PBS, even when the
immune presentation performed in this manner lacks the
‘‘depot’’ properties of an oil-in-water adjuvant emulsion
provided by the Ribi formulation. The use of such a
molecular adjuvant could be of benefit for enhancing the
immune responses elicited by DNA inoculation, as has been
demonstrated by Ross and colleagues (Bower et al., 2004a,
2004b; Ross et al., 2001). As also suggested by these
investigators, the use of C3d-mediated immune enhance-
ment could also be of benefit to better maintain the native
conformation of recombinant HIV Env trimeric proteins.
The native structure of these proteins is normally assessed
under physiological conditions and it may be important, if
not critical, to keep these trimeric proteins in as native an
environment as possible to present the most relevant
structures to the host humoral immune system. As shown
here, however, if one uses an oil-in-water emulsifying
adjuvant that also targets TLR-4, there is not a large benefit
to the addition of the C3d elements in a fusion protein. A
slight benefit in gp120-specific IgG secondary antibody
elicitation was observed by gp120DC1/C5(C3d)2 priming
followed by two gp120DC1/C5 boosts compared to using
either protein alone for all three inoculations. Since this
experiment is internally well controlled for protein dose, we
interpret these minor differences to be slight but meaningful.
The gp120-C3d likely functions more efficiently as a prime
even in the presence of Ribi, and then boosting without C3d
may serve to focus the immune response toward gp120-
specific elements and not divert potential antigenic inter-
action to non-primed or non-gp120-specific cells bearing
CD21 or other C3d-binding proteins (Haas et al., 2004).
Since this study utilized two fused repeats of C3d, it is
possible that greater numbers of C3d repeats, or at lower
protein doses, or if C3d is used on trimeric gp140 constructs
as was recently done (Bower et al., 2004a, 2004b), there
might be a greater benefit even in the presence of a classical
oil-in-water adjuvant. We conclude that C3d may merit
consideration for selected uses in candidate HIV-1 immu-
nogens and that generally the activation of innate immunity
through multiple pathways merits further investigation.Materials and methods
Plasmid construction, transient expression and
establishment of stable insect lines
Deletions of the N- and C-termini of gp120 were
performed by PCR amplification and in-frame cloning into
a C3d expression vector to create a gp120(C3d)2 fusion
protein as follows. To introduce the deletions, gp120 coding
sequences were PCR amplified utilizing homologous for-
ward and reverse primers designed to eliminate coding
sequences for the first 82 residues from the N-terminus ofgp120 and the last 19 amino acids from the C-terminus of
gp120 (gp120DC1/C5). Purified PCR products were then
directionally cloned into a gp120 mammalian expression
vector, pSVIII (Helseth et al., 1990), in which expression is
driven in a rev- and tat-dependent manner from a mini LTR.
Tat is provided in trans by the co-transfection of the pSVtat
expression plasmid. Previous analysis of this gp120 variant
transiently expressed in 293T cells had indicated that this
protein was recognized by a set of conformationally
sensitive antibodies and bound CD4 with wild-type affinity
(Wyatt et al., 1997).
To create a gp120DC1/C5(C3d)2 fusion protein, the
mammalian expressor plasmid pSG5(C3d)2 was kindly
provided by Drs. Douglas Fearon and Paul Dempsey
(Dempsey et al., 1996) and contains two repeats of the
murine C3d coding sequence in a continuous open reading
frame. Immediately 5V to the C3d coding sequences was a
BglII restriction site that allowed in-frame cloning of gp120
coding sequences. Located between the two C3d coding
cassettes were sequences encoding a flexible (Gly4Ser)2
linker designed to permit independent interaction of each
C3d subunit with a CD21 molecule. Sequences coding for
the gp120DC1/DC5 were PCR amplified from the pSVIII
molecular clone utilizing primers possessing BglII sites and
shuttled into the pSG5(C3d)2 vector in the proper orienta-
tion. To make recombinant gp120DC1/C5(C3d)2 fusion
proteins, coding sequences were directionally subcloned
from the pSG5(C3d)2 shuttle vector into the pMtdel0
plasmid (Culp et al., 1991; Ivey-Hoyle et al., 1991). The
pMt plasmid drives expression from the inducible Droso-
phila metallothionein promoter when transfected into
Drosophila Schneider 2 (S2) cells and induced by heavy
metals (Culp et al., 1991). Stable S2 producer cell lines were
established by co-transfection with a hygromycin resistance
plasmid and selection in hygromycin-containing media
(Culp et al., 1991; Ivey-Hoyle et al., 1991).
Protein characterization and purification
To produce quantities of proteins sufficient for immuno-
genicity studies, and following selection of stably producing
Drosophila S2 cell lines, expression of the gp120DC1/C5
and the gp120DC1/C5(C3d)2 fusion proteins were induced
by the addition of 750 um CuSO4 to the media. The proteins
were purified to near homogeneity by affinity chromatog-
raphy using an F105 affinity column as previously described
(Wu et al., 1996). The F105 antibody recognizes a
discontinuous gp120 epitope overlapping the CD4 binding
site and thus selects for properly folded glycoproteins. The
concentration of each protein was determined by optical
density at 280 nm and by SDS gels to confirm purity and that
the calculated concentrations were accurate (Fig. 2A). To
confirm the gp120 structural integrity, glycoproteins were
radiolabeled with 125I by the lactoperoxidase method as
described previously (Wu et al., 1996) and immunoprecipi-
tations were performed by the addition of AIDS patient sera,
M. Koch et al. / Virology 340 (2005) 277–284 283two gp120-specific antibodies (F105 and 17b) andwith sCD4
in combination with a rabbit anti-CD4 antibody followed by
the addition of protein A sepharose (Fig. 2B). Two polyclonal
sera against murine C3 and human C3d were also included in
the immunoprecipitation analysis (Fig. 2B).
To confirm that the C3d was functional, we incubated
125-labeled gp120DC1/C5 or gp120DC1/C5(C3d)2 with
CD21+ Raji B cells in complete media for 1 h at RT.
Following extensive washing, the cells were lysed in NP-40
buffer, immunoprecipitated with HIV patient serum and
analyzed by SDS gels and autoradiography (Fig. 2C).
Inoculation of mice with selected variant gp120
glycoproteins
Groups of mice were immunized with 20 Ag of selected
gp120 variant glycoproteins by the subcutaneous route in the
presence of either PBS (no adjuvant) or Ribi Adjuvant
System (RAS; Sigma or Corixa). The Ribi formulation used
here, and recommended by the manufacture for use in mice
with a diverse range of immunogens (R-700, Corixa),
contains squalene oil, polysorbate 80, synthetic trehalose
dicorynomycolate (TDM) and MPL. Approximately 28 days
apart, either three or four inoculations were administered and
7–10 days after each inoculation retro-orbital test bleeds
were obtained. The serum isolated from the bleeds was
analyzed for gp120 recognition by ELISA with either
gp120DC1/C5 or gp120DC1/C5(C3d)2 proteins coated on
the plates.
ELISA gp120 binding assays
To detect antibodies capable of binding to HIV-1 gp120,
the gp120DC1/C5 or gp120 DC1/C5(C3d)2 proteins were
coated overnight onto 96-well ELISA plates at 200 ng/well in
0.1 M sodium carbonate–bicarbonate buffer, pH 9.6.
Following a wash to remove unbound proteins, the wells
were incubated with blocking buffer (bb) that was composed
of PBS containing 5% heat-inactivated fetal calf serum and
2% non-fat driedmilk (Carnation) for 2 h at room temperature
(RT). The sera were serially diluted in bb and incubated for 2
h at RT on the ELISA plate and following extensive washing
in PBS with 2% TWEEN, anti-mouse horseradish peroxidase
was added to all wells for 1 h at RT. Following a second
extensive wash, 100 Al of substrate was added and the
colorimetric reaction was stopped by adding an equal volume
of 1 N hydrochloric acid. Optical density readings at 450 nM
were used to detect binding antibodies to the gp120 variant
proteins. For ease of comparison between ELISAs, the data
were normalized and plotted as relative absorbance.Acknowledgments
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